Spasticity - Epidemiology Forecast - 2032

DelveInsight's 'Spasticity Overview - Epidemiology Forecast-2032' report delivers an in-depth understanding of the spasticity historical and forecasted epidemiology as well as the spasticity epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Spasticity Understanding

Spasticity Overview

Spasticity is a condition in which there is an abnormal increase in muscle tone or muscle stiffness, which might interfere with movement and speech or be associated with discomfort or pain. Spasticity may be associated with spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Symptoms may include hypertonicity (increased muscle tone), clonus (a series of rapid muscle contractions), exaggerated deep tendon reflexes, muscle spasms, scissoring (involuntary crossing of the legs), and fixed joints (contractures). The degree of spasticity varies from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms. Spasticity can interfere with rehabilitation in patients with certain disorders and often interferes with daily activities.

Continued in the report…

Spasticity Pathophysiology

The pathophysiologic basis of spasticity is incompletely understood. Polysynaptic responses may be involved in the spinal cord-mediated spasticity, while enhanced excitability of monosynaptic pathways is involved in cortically mediated spasticity. Spasticity-related changes in muscle tone probably result from alterations in the balance of inputs from reticulospinal and other descending pathways to the motor and interneuronal circuits of the spinal cord, along with the absence of an intact corticospinal system. Loss of descending tonic or phasic excitatory and inhibitory inputs to the spinal motor apparatus, alterations in the segmental balance of excitatory and inhibitory control, denervation super sensitivity, and neuronal sprouting may be observed.

Continued in the report…

Spasticity Clinical Presentation

Spasticity in cerebral palsy

In a person with cerebral palsy (CP), brain damage is in the area that controls muscle tone and movement of the arms and legs. Therefore, the brains of people with cerebral palsy cannot influence the number of flexibility muscles should have. The command from the muscle itself dominates the spinal cord and results in muscles that are too tense or spastic. The patients born with cerebral palsy do not have deformities of the extremities present at birth but develop them over time. Spasticity of muscles, along with the limitations on stretching and the use of muscles in daily activities, is a major cause of these deformities.

Spasticity in multiple sclerosis

Spasticity is one of the most common symptoms of multiple sclerosis (MS) and is defined as muscle stiffness that is frequently generalized and causes more or less continuous rigidity. It is normally associated with temporary periods of worsening in the form of involuntary muscle spasms, and all the while, muscle function is progressively lost. Spasticity is one of the primary reasons for disability in multiple sclerosis since it is associated with pain, changes in bladder function and sleep, and the inability to walk and perform other movements, including those required for personal hygiene.

Continued in the report…..

Spasticity Epidemiology Perspective by DelveInsight

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Spasticity, Indication-specific Cases of Spasticity, and Severity-specific Cases of Spasticity scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Spasticity Detailed Epidemiology Segmentation

• In 2021, the total cases of spasticity were ~7,871,000 in the 7MM which are expected to increase by 2032.
• The United States, in 2021, accounted for the highest number of cases of spasticity (~4,756,000 cases). These cases are expected to increase by the year 2032.
• In 2021, Japan accounted for ~823,000 cases of spasticity, which was approximately 10% of the total spasticity cases in 7MM.
• The total number of mild, moderate, and severe spasticity cases in the 7MM was ~1,504,000; ~2,424,000; and ~1,582,000 in 2021.
• In 2021, the total number of spasticity cases due to cerebral palsy, multiple sclerosis, post-stroke, traumatic brain injury, and spinal cord injury were ~533,000; ~499,000; ~689,000; ~472,000; and ~98,000 respectively in the EU5.

Scope of the Report:

• The report covers a descriptive overview of spasticity, explaining its associated indications, and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the spasticity risk and burden.
• The report provides the segmentation of the epidemiology for 7MM by segmented by 'Total Cases of Spasticity, Indication-specific Cases of Spasticity, and Severity-specific Cases of Spasticity'.

Report Highlights:

• 11-Year Forecast of spasticity
• 7MM Coverage
• Total Cases of Spasticity
• Indication-specific Cases of Spasticity
• Severity-specific Cases of Spasticity

Key Questions Answered

• What are the risk, burdens, and unmet needs of spasticity?
• What is the historical spasticity patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of spasticity at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to spasticity?
• Out of the countries mentioned above, which country would have the highest cases of spasticity during the forecast period (2022-2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Reasons to buy:

The spasticity report will allow the user to -

• Develop business strategies by understanding the trends, shaping and driving the 7MM spasticity epidemiology.
• The spasticity epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The spasticity epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Geographies Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032.